SCHEMBL676145

SCHEMBL676145

CCOCn1c2ccccc2c2ccc(C#CC3=CCCCC3)nc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.41
GRM5 P41594 2/20 0.41
ATM Q13315 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 4/20 0.31
KDM4E B2RXH2 3/20 0.31
HPGD P15428 3/20 0.31
TSHR P16473 3/20 0.31
HSD17B10 Q99714 3/20 0.31
ALOX15 P16050 2/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
GAA P10253 1/20 0.31
MEN1 O00255 3/20 0.31
KMT2A Q03164 3/20 0.31
USP2 O75604 2/20 0.31
TP53 P04637 2/20 0.31
CASP1 P29466 2/20 0.31
CASP7 P55210 2/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679427 0.82 RAB9A (0.55) CYP1A2GRM5ATMNPC1RAB9A
SCHEMBL676181 0.80 GRM5 (0.42) CYP1A2GRM5ATMNPC1RAB9A
SCHEMBL675907 0.77 GRM5 (0.39) CYP1A2GRM5ATMNPC1RAB9A
SCHEMBL674752 0.71 PTGER4 (0.49) CYP1A2ATMNPC1ALDH1A1KDM4E
SCHEMBL676186 0.63 POLB (0.41) NPC1RAB9AALDH1A1KDM4EHPGD
SCHEMBL4855899 0.63 GRM5 (0.59) CYP1A2GRM5NPC1RAB9AALDH1A1
SCHEMBL676114 0.62 PTGER4 (0.56) GRM5ATMALDH1A1KDM4EHPGD
SCHEMBL13553021 0.60 MEN1 (0.49) CYP1A2ALDH1A1KDM4EHPGDTSHR
SCHEMBL677949 0.60 RAB9A (0.50) CYP1A2GRM5ATMNPC1RAB9A
SCHEMBL676791 0.60 PTGER4 (0.49) CYP1A2ATMALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
WO-2010025872-A2 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2010-03-11 WO disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 CYP1A2 1915/4885GRM5 3229/4885ATM 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.